Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.

Halappanavar, Sabina; Nymark, Penny; Krug, Harald F; Clift, Martin J D; Rothen-Rutishauser, Barbara; Vogel, Ulla

Halappanavar, Sabina; Nymark, Penny; Krug, Harald F; Clift, Martin J D; Rothen-Rutishauser, Barbara; Vogel, Ulla.

Afiliación

Halappanavar S; Environmental Health Science and Research Bureau, Health Canada, Ottawa, K1A0K9, Canada.
Nymark P; Department of Biology, University of Ottawa, Ottawa, K1N6N5, Canada.
Krug HF; Institute of Environmental Medicine, Karolinska Institute, Nobels väg 13, Stockholm, 17177, Sweden.
Clift MJD; NanoCASE GmbH, St. Gallerstr. 58, Engelburg, 9032, Switzerland.
Rothen-Rutishauser B; Institute of Life Science, Swansea University Medical School, Swansea University, Singleton Park, Swansea, Wales, SA2 8PP, UK.
Vogel U; Adolphe Merkle Institute, University of Fribourg, Chemin des Verdiers 4, Fribourg, 1700, Switzerland.

Small ; 17(15): e2007628, 2021 04.

Article en En | MEDLINE | ID: mdl-33559363

Asunto(s)

Rutas de Resultados Adversos; Nanoestructuras; Fibrosis Pulmonar; Alternativas a las Pruebas en Animales; Animales; Nanoestructuras/toxicidad; Medición de Riesgo

Palabras clave

in vitro toxicity; lung fibrosis; nanoparticles; nanotoxicity; risk assessment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fibrosis Pulmonar / Nanoestructuras / Rutas de Resultados Adversos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Small Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google